$4.82
5.30% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
US3441741077
Symbol
FHTX
Sector
Industry

Foghorn Therapeutics Inc Stock price

$4.82
-2.97 38.13% 1M
-0.92 16.03% 6M
-1.63 25.27% YTD
-1.85 27.74% 1Y
-16.36 77.24% 3Y
-11.18 69.88% 5Y
-11.18 69.88% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.27 5.30%
ISIN
US3441741077
Symbol
FHTX
Sector
Industry

Key metrics

Market capitalization $267.96m
Enterprise Value $39.63m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.55
P/S ratio (TTM) P/S ratio 10.50
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -21.66%
Revenue (TTM) Revenue $25.52m
EBIT (operating result TTM) EBIT $-101.74m
Free Cash Flow (TTM) Free Cash Flow $-103.89m
Cash position $267.40m
EPS (TTM) EPS $-1.91
P/E forward negative
P/S forward 9.10
EV/Sales forward 1.35
Short interest 2.11%
Show more

Is Foghorn Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Foghorn Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Foghorn Therapeutics Inc forecast:

6x Buy
86%
1x Hold
14%

Analyst Opinions

7 Analysts have issued a Foghorn Therapeutics Inc forecast:

Buy
86%
Hold
14%

Financial data from Foghorn Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
26 26
22% 22%
100%
- Direct Costs 3.19 3.19
60% 60%
13%
22 22
9% 9%
88%
- Selling and Administrative Expenses 26 26
25% 25%
101%
- Research and Development Expense 95 95
14% 14%
372%
-99 -99
7% 7%
-386%
- Depreciation and Amortization 3.19 3.19
60% 60%
13%
EBIT (Operating Income) EBIT -102 -102
11% 11%
-399%
Net Profit -91 -91
12% 12%
-357%

In millions USD.

Don't miss a Thing! We will send you all news about Foghorn Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Foghorn Therapeutics Inc Stock News

Neutral
GlobeNewsWire
13 days ago
Objective clinical responses by standard response criteria observed in Phase 1 dose escalation trial for FHD-286 in combination with decitabine in patients with relapsed and/or refractory AML; efficacy threshold not achieved to support continued development by Foghorn alone
Neutral
GlobeNewsWire
about 2 months ago
CAMBRIDGE, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced management's participation in the Jefferies London Healthcare Conference, the 7th Annual Evercore HealthCONx Conference, and the Citi Global He...
Neutral
GlobeNewsWire
about 2 months ago
First patient dosed with first-in-class SMARCA2(BRM) selective inhibitor FHD-909 (LY4050784) in Phase 1 trial with primary target population in SMARCA4(BRG1) mutated NSCLC
More Foghorn Therapeutics Inc News

Company Profile

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.

Head office United States
CEO Adrian Gottschalk
Employees 116
Founded 2015
Website www.foghorntx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today